Rae Lab Publications

Person using laptop in a lab

Explore our latest publications.

Recent Publications

 

  1. Targeting monopolar spindle kinase I (Mps1 or TTK) induces radiosensitization in syngeneic models of triple negative breast cancer (TNBC) and potentiates type I interferon (T1IFN) signaling. Kassidy M Jungles, Caroline R Bishop, Cydnee M Wilson, Meilan Liu, Kalli R Jungles, Kari Wilder-Romans, Corey W Speers, Lori J Pierce, James M Rae. Neoplasia, 2025 Aug 1; 66, 101190.
  2. Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial. Shane R Stecklein, William E Barlow, Jill Tsai, Arielle Yablonovitch, Eve Rodler, Peter Kuhn, James Hicks, Harsh B Pathak, Daniel F Hayes, James M Rae, Gabriel N Hortobagyi, Alastair Mark Thompson, Andrew K Godwin, Lajos Pusztai, Priyanka Sharma. Journal of Clinical Oncology 2025 43:16_suppl, 1012-1012
  3. Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer. Pusztai L, Hoag JR, Albain KS, Barlow WE, Stemmer SM, Meisner A, Hortobagyi GN, Shak S, Rae JM, Baehner R, Sharma P, Kalinsky KM. Journal of Clinical Oncology, 2025 Mar 10; 43 (8): 919 - 928. PMID: 39621968.
  4. Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular Dysfunction. Shugg T, Nguyen T, Hua X, Richards B, Rae J, Dess R, Perry D, Kay B, Hayek SS, Leja M, Luzum JA. Journal of Cardiovascular Pharmacology and Therapeutics, 2025 Jan 1; 30. PMID: 39801159.
  5. Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα). Rej RK, Hu B, Chen Z, Acharyya RK, Wu D, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Nishimura LS, Gersch CL, Wang M, Wen B, Sun D, Carlson K, Katzenellenbogen JA, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Rae JM, Wang S. Journal of Medicinal Chemistry, 2024 Dec 12; 67 (23): 20933 - 20965. PMID: 39585895.
  6. Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL, Agema BC, Sanchez-Spitman A, Almeida T, Nardin J, Casali-da-Rocha JC, Moo-Puc RE, Rangel-Mendez JA, McMillin G, Hennig EE, Brewczyńska E, Venzon Antunes M, Haufroid V, Thorén L, Madlensky L, Pierce J, Nakaumra Y, Kubo M, Zembutsu H, Bianchi Ximenez JP, Lanchote VL, Rae JM, Hayes DF, Stearns V, Skaar TC, Desta Z, Scott SA, Desnick RJ, Park IH, Woo HI, Lee SY, Fernandez-Santander A, Romero-Lorca A, Villajos AN, Alonso MG, Johansson H, Bonanni B, DeCensi A, Gurney H, Balleine R, Irvin WJ, McLeod HL, Goetz MP, Reid JM, Suman VJ, Areepium N, Charoenchokthavee W, Eccles D, Tapper W, Chowbay B, Khor CC, Hsuen EL, Tfayli A, Zgheib NK, Arellano C. Clinical Pharmacology and Therapeutics, 2024 Sep 1; 116 (3): 690 - 702. PMID: 38494911.
  7. Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advances. Bryant AK, Zamora-Resendiz R, Dai X, Morrow D, Lin Y, Jungles KM, Rae JM, Tate A, Pearson AN, Jiang R, Fritsche L, Lawrence TS, Zou W, Schipper M, Ramnath N, Yoo S, Crivelli S, Green MD. Cancer Medicine, 2024 Jun 1; 13 (12).
  8. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms. Liang Y, Gersch CL, Lehman J, Henry NL, Smith KL, Rae JM, Stearns V, Hertz DL. Pharmacogenetics and Genomics, 2024 Jun 1; 34 (4): 126 - 129. PMID: 38359166.